Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis

Journal of Clinical Investigation

Volumn 123, Issue 8, 2013, Pages 3436-3445

  Ziegler, Tilman ^a   Horstkotte, Jan ^a   Schwab, Claudia ^b   Pfetsch, Vanessa ^a   Weinmann, Karolina ^a   Dietzel, Steffen ^a   Rohwedder, Ina ^c   Hinkel, Rabea ^a,d   Gross, Lisa ^a   Lee, Seungmin ^a   Hu, Junhao ^e   Soehnlein, Oliver ^a,d   Franz, Wolfgang M ^a,d   Sperandio, Markus ^a   Pohl, Ulrich ^a,d   Thomas, Markus ^f   Weber, Christian ^a,d   Augustin, Hellmut G ^e   Fässler, Reinhard ^c,d   Deutsch, Urban ^b   Kupatt, Christian ^a,d   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; COMPLEMENTARY DNA;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL LOSS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; ENDOTOXEMIA; HEART MUSCLE CELL; HEART OUTPUT; HEMODYNAMICS; HYPOTENSION; MORTALITY; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPTIC SHOCK; SYSTOLIC BLOOD PRESSURE;

EID: 84881246880     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66549     Document Type: Article

References (44)

1. Dumont DJ, et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 1994;8(16):1897-1909.
2. Sato TN, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995;376(6535):70-74.
3. Jeansson M, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest. 2011; 121(6):2278-2289.
4. Suri C, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87(7):1171-1180.
5. Maisonpierre PC, et al. Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis. Science. 1997;277(5322):55-60.
6. Thomas M, et al. Angiopoietin-2 stimulation of endothelial cells induces alphavbeta3 integrin internalization and degradation. J Biol Chem. 2010;285(31):23842-23849.
7. Felcht M, et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest. 2012;122(6):1991-2005.
8. Parikh SM, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med. 2006;3(3):e46.
9. Kumpers P, et al. Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Med. 2010;36(3):462-470.
10. Alves BE, et al. Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia. BMC Infect Dis. 2010;10:143.
11. van der Heijden M, van Nieuw Amerongen GP, Van Hinsbergh VW, Groeneveld AB. The interaction of soluble Tie2 with angiopoietins and pulmonary vascular permeability in septic and nonseptic critically ill patients. Shock. 2010;33(3):263-268.
12. Armulik A, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468(7323):557-561.
13. Roviezzo F, et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther. 2005;314(2):738-744.
14. Thurston G, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin- 1. Science. 1999;286(5449):2511-2514.
15. Sundberg C, Kowanetz M, Brown LF, Detmar M, Dvorak HF. Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest. 2002;82(4):387-401.
16. Hammes HP, et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes. 2004;53(4):1104-1110.
17. Tidhar A, et al. A novel transgenic marker for migrating limb muscle precursors and for vascular smooth muscle cells. Dev Dyn. 2001;220(1):60-73.
18. Feng Y, et al. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost. 2007;97(1):99-108.
19. Fuxe J, et al. Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. Am J Pathol. 2011;178(6):2897-2909.
20. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21(2):193-215.
21. Kumpers P, et al. Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. Crit Care. 2009;13(3):R64.
22. Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C. Protective role of angiopoietin-1 in endotoxic shock. Circulation. 2005;111(1):97-105.
23. David S, et al. Acute administration of recombinant Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis. Cytokine. 2011;55(2):251-259.
24. De Domenico I, et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest. 2010;120(7):2395-2405.
25. Tzepi IM, et al. Angiopoietin-2 enhances survival in experimental sepsis induced by multidrug-resistant Pseudomonas aeruginosa. J Pharmacol Exp Ther. 2012;343(2):278-287.
26. Korff T, et al. Angiopoietin-1 mediates inhibition of hypertension-induced release of angiopoietin- 2 from endothelial cells. Cardiovasc Res. 2012;94(3):510-518.
27. Reiss Y, et al. Angiopoietin-2 impairs revascularization after limb ischemia. Circ Res. 2007;101(1):88-96.
28. Dore-Duffy P, et al. Pericyte-mediated vasoconstriction underlies TBI-induced hypoperfusion. Neurol Res. 2011;33(2):176-186.
29. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest. 1997;100(12):3131-3139.
30. Ziche M, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor- induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997; 99(11):2625-2634.
31. Lopez JJ, et al. Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol. 1997;273(3 pt 2):H1317-H1323.
32. Sato K, et al. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol. 2001;37(2):616-623.
33. Ahmed A, et al. Angiopoietin-2 Confers atheroprotection in apoE-/- mice by inhibiting ldl oxidation via nitric oxide. Circ Res. 2009;104(12):1333-1336.
34. Yu J, et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci U S A. 2005;102(31):10999-11004.
35. Lindblom P, et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Gene Dev. 2003;17(15):1835- 1840.
36. Nystrom HC, et al. Platelet-derived growth factor B retention is essential for development of normal structure and function of conduit vessels and capillaries. Cardiovasc Res. 2006;71(3):557-565.
37. Schlaeger TM, Qin Y, Fujiwara Y, Magram J, Sato TN. Vascular endothelial cell lineage-specific promoter in transgenic mice. Development. 1995;121(4):1089-1098.
38. Deutsch U, et al. Inducible endothelial cell-specific gene expression in transgenic mouse embryos and adult mice. Exp Cell Res. 2008;314(6):1202-1216.
39. Yu Z, Redfern CS, Fishman GI. Conditional transgene expression in the heart. Circ Res. 1996;79(4):691-697.
40. Horstkotte J, et al. Mitochondrial thioredoxin reductase is essential for early postischemic myocardial protection. Circulation. 2011;124(25):2892-2902.
41. Zaruba MM, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell. 2009;4(4):313-323.
42. Rehberg M, Krombach F, Pohl U, Dietzel S. Labelfree 3D visualization of cellular and tissue structures in intact muscle with second and third harmonic generation microscopy. PLoS One. 2011;6(11):e28237.
43. Bish LT, et al. AAV9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther. 2008;19(12):1359-1368.
44. Thomas M, et al. A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to pan-angiopoietin-1/-2 inhibitors. PLoS One. 2013;8(2):e54923.